Volume 37 Issue 3, March 2019

NASH has replaced hepatitis C as the most important nonalcoholic liver disease. Biotech and pharma are racing to tap into this enormous market.

In the face of the Supreme Court’s double-novelty requirement and the negative impact that requirement has had on biotechnology, the time has come for a new paradigm of law.

Recent patents related to sequencing methods and devices.

Chien et al. reflect on lessons learned following the recent announcement that 31 papers from the Anversa laboratory on cardiac cell therapy are being retracted.

Pere Santamaria and Pau Serra review the state of the art in antigen-specific therapies for autoimmune disease, discussing mechanism of action and clinical efficacy of each strategy.

Genetic engineering prevents immune rejection of allogeneic cell transplants derived from iPSCs.

Measuring proliferation history in single-cell mass cytometry enables control of T cell fate.

A new method generates astrocytes from human pluripotent stem cells in 5 days.

Structure-guided protein engineering of Cas12a yields variants that have increased activity and that can edit sites with previously inaccessible PAMs.

Hybrids can be self-pollinated to produce true-breeding progeny through seeds by simultaneous genome editing of four endogenous genes in a rice F₁ hybrid variety.

Genome editing is induced in seeds during haploid induction, thereby enabling genome editing in monocot and dicot crops.

A bone marrow–like scaffold improves T cell regeneration after hematopoietic stem cell transplantation.

‘Tubuloids’ grown from human kidney tissue and urine aid the study of BK virus infection, Wilms tumors and cystic fibrosis.

Systems-wide analysis of HeLa cell lines from 13 labs identifies substantial molecular and phenotypic variability.

Providing training and access to standard computing hardware and cloud-based resources can enable scientists in lower-resource institutions and countries to reanalyze published ‘-omics’ data and produce career-enhancing STEM research.

A sample of goings-on in and around the biotech and pharmaceutical industry.